188863-87-8Relevant articles and documents
HETEROCYCLIC COMPOUND
-
, (2015/04/15)
The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
Synthesis of 4-arylpiperidines from 1-benzyl-4-piperidone: Application of the shapiro reaction and alkenylsilane cross-coupling
Morrill, Christie,Mani, Neelakandha S.
, p. 1505 - 1508 (2008/02/02)
Equation Presented 1-Benzyl-3,4-unsaturated-4-piperidinyl benzyldimethylsilane has been prepared and observed to readily undergo palladium-catalyzed cross-coupling reactions with a variety of aryl iodides and aryl bromides to generate 3,4-unsaturated 4-arylpiperidines, often at ambient temperature.
Structural changes of benzylether derivatives of vesamicol and their influence on the binding selectivity to the vesicular acetylcholine transporter
Wenzel, Barbara,Sorger, Dietlind,Heinitz, Katrin,Scheunemann, Matthias,Schliebs, Reinhard,Steinbach, J?rg,Sabri, Osama
, p. 1197 - 1205 (2007/10/03)
18F labelled vesamicol analogues, which bind to the vesicular acetylcholine transporter (VAChT) in central cholinergic nerve terminals, are expected to be potential radioligands for the visualisation of cholinergic transmission deficits via pos